Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Pharma Wholesalers: Looking for Growth

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

340B Litigation and the Path Toward Transparent Drug Discount Programs

Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

Beginning Oct. 1, the US will impose a 100% tariff on branded and patented pharmaceutical imports unless manufacturers are actively building domestic production facilities, a move aimed at reshoring drug manufacturing.

Trump Announces 100% Tariff on Branded Drugs Unless Pharma Builds US Plants

Capturing insights from executives and industry experts on the biggest challenges shaping pharma today, from drug pricing pressures and access barriers to supply chain shifts, digital adoption, and evolving patient-centered care strategies.

Pharma Commerce's 2025 State of the Industry Survey

Podcasts

This episode of Pharma Pulse covers new research showing Medicaid cuts could widen pediatric coverage gaps, clinical trial data on a fixed-dose combination therapy lowering heart failure risk in type 2 diabetes, and Bristol Myers Squibb’s launch of a direct-to-patient program for Sotyktu to improve psoriasis treatment access.

Pharma Pulse: Medicaid Cuts Threaten Childhood Coverage, Fixed-Dose Combo Reduces Heart Failure in Diabetes, and BMS Expands Sotyktu Access

Through its “BMS Patient Connect” platform, the company is lowering out-of-pocket costs and providing nationwide shipping, making the treatment for affordable and accessible for US patients.

Bristol Myers Squibb Expands Direct-to-Patient Access With New Sotyktu Program

Videos

Ullrich Mayeski, community engagement director of health with GS1 US, emphasizes the critical need to address interoperability challenges at the dispenser level, ranging from small independent pharmacies to large hospital systems. 

HDA 2025 Traceability Seminar: Closing Gaps in Pharma’s Supply Chain

This episode of Pharma Pulse covers the CDC’s unanimous vote to broaden COVID-19 vaccine recommendations for all adults, new data showing the Medicare Part D Senior Savings Model lowers insulin costs and improves care, and Eli Lilly’s investment in a new Houston manufacturing facility to support its fast-growing pipeline.

Pharma Pulse: CDC Expands COVID-19 Vaccine Guidance, Medicare Model Cuts Insulin Costs, and Lilly Invests in Houston Facility

Ullrich Mayeski, community engagement director of health with GS1 US, outlines how manufacturers, distributors, and dispensers can strengthen end-to-end traceability. 

HDA 2025 Traceability Seminar: Building a Secure and Interoperable Supply Chain

The Generation Park site will create over 600 permanent jobs, support advanced small molecule production, and play a role in scaling orforglipron, Lilly’s first oral GLP-1 receptor agonist for obesity.

Eli Lilly to Invest $6.5 Billion in New Houston Manufacturing Facility

This episode of Pharma Pulse covers the FDA’s review of a possible link between prenatal acetaminophen use and autism, GSK’s supplemental new drug application to update leucovorin labeling, and Celltrion’s acquisition of an Eli Lilly production facility to expand biologics manufacturing capacity.

Pharma Pulse: FDA Examines Prenatal Acetaminophen Risks, GSK Files sNDA for Leucovorin, and Celltrion Buys Lilly Plant

Ullrich Mayeski, community engagement director of health with GS1 US, explains how with over a decade of collaboration, manufacturers and distributors are largely prepared for DSCSA compliance. The remaining challenge lies in ensuring consistent readiness across dispensers, while maintaining open communication throughout the supply chain.

HDA 2025 Traceability Seminar: Pharma Industry Shows Strong Readiness for DSCSA Enforcement

The South Korean pharma company’s US subsidiary is purchasing Eli Lilly’s Branchburg, NJ site to safeguard against potential tariffs. strengthen domestic production, and expands its biosimilar footprint.

Celltrion to Acquire Eli Lilly’s $330M Production Plant

This episode of Pharma Pulse covers ACIP’s move toward shared decision-making for COVID-19 vaccines, Pfizer’s acquisition of Metsera to strengthen its obesity and cardiovascular pipelines, and Closed Loop Medicine’s partnership with Wedosify to improve patient adherence to GLP-1 therapies.

Pharma Pulse: CDC Shifts COVID-19 Vaccine Guidance, Pfizer Buys Metsera for Obesity Pipeline, and New Tech Targets GLP-1 Adherence

Ullrich Mayeski, community engagement director of health with GS1 US, describes the organization’s EPCIS standard for meeting DSCSA requirements while underscoring that true supply chain success depends on robust data quality practices, clear procedures, and cross-team accountability to ensure patients receive their medications without disruption.

HDA 2025 Traceability Seminar: Data Quality and EPCIS Standards Take Center Stage 

The platform enables clinicians to tailor GLP-1 titration at scale, aiming to reduce discontinuation rates and improve long-term outcomes for patients undergoing obesity treatment.

Closed Loop Medicine Debuts WeDosify in US to Personalize GLP-1 Dosing and Improve Patient Adherence

This episode of Pharma Pulse covers the CDC’s decision to postpone changes to Hepatitis B vaccine guidance, new research showing value-based care improves visit frequency and consistency for seniors, and Takeda’s partnership with VELA to launch wind-powered transport for medicines.

Pharma Pulse: CDC Delays Hepatitis B Vaccine Vote, Value-Based Care Improves Senior Access, and Takeda Tests Wind-Powered Shipping

Takeda will be shipping treatments between Europe and the US using VELA’s sailing cargo trimaran, potentially reducing greenhouse gas emissions by up to 99% when compared with air freight.

Takeda Partners with VELA to Launch Wind-Powered Medicine Transport Across the Atlantic

Industry leaders—from manufacturers, distributors, and dispensers—reported increased preparedness for compliance, with discussions shifting toward exception management, governance, and enforcement readiness, note Ullrich Mayeski of GS1 US and Mark Karhoff of Ten Count Consulting.

HDA 2025 Traceability Seminar: Confidence Grows Across Pharma Supply Chain

New bipartisan legislation would give the FDA authority to modernize prescribing information, reducing waste while improving accuracy and patient care.

Congress Revives Push to Digitize Prescription Information

This episode of Pharma Pulse covers GSK’s $30 billion plan to expand US biopharma production, new evidence that weekly GLP-1 therapies significantly reduce cardiovascular risks, and Roche’s acquisition of 89bio to add the FGF21 analog Pegozafermin to its growing metabolic disease portfolio.

Pharma Pulse: GSK Invests $30B in US Manufacturing, GLP-1s Show Heart Benefits, and Roche Buys 89bio for Metabolic Pipeline

The pharmaceutical giant’s commitment includes a $1.2 billion investment in advanced facilities powered by AI and digital technology, strengthening biopharma manufacturing and clinical research across the United States.

Featured Content

Pharma Wholesalers: Looking for Growth

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

340B Litigation and the Path Toward Transparent Drug Discount Programs

Pharmaceutical Commerce - August 2025